title: Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity.
abstract: Gastric cancer with peritoneal carcinomatosis has an extremely poor prognosis, which may be improved with cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC). We systematically reviewed the literature regarding the efficacy of CRS + HIPEC in these patients. Electronic databases were searched from 2000 to 2010. Following CRS + HIPEC, overall median survival was 7.9 months and improved to 15 months for patients with completeness of cytoreduction scores of 0/1, however with a 30-day mortality rate of 4.8%.
authors.affiliation: Department of Surgery, University of Alberta, Edmonton, Alberta, Canada. richdeep@ualberta.ca
authors.forename: Richdeep S
authors.initials: RS
authors.lastname: Gill
authors.forename: David P
authors.initials: DP
authors.lastname: Al-Adra
authors.forename: Jeevan
authors.initials: J
authors.lastname: Nagendran
authors.forename: Sandy
authors.initials: S
authors.lastname: Campbell
authors.forename: Xinzhe
authors.initials: X
authors.lastname: Shi
authors.forename: Erika
authors.initials: E
authors.lastname: Haase
authors.forename: Daniel
authors.initials: D
authors.lastname: Schiller
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D010534:Peritoneal Neoplasms / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D013274:Stomach Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents